Clinical trials: Diabetic Maculopathy
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema…
- Trial name
- Tejas (NCT05387837)
- Testing
- D-4517.2
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with…
- Trial name
- NCT01997164
- Testing
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Degeneration, Diabetic Retinopathy
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible…
- Trial name
- NCT00414999
- Testing
- TG100801
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- TargeGen
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Diabetes, Macular Edema
Research Study in Patients With Persistent Macular Edema
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods.
- Conditions
- Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease
- Trial name
- NCT00035906
- Testing
- DEX PS DDS®
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Macular Edema
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
- Trial name
- NCT02186119
- Testing
- abicipar pegol, ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 151 people
- Sponsor
- Allergan
Diabetic Macular Edema
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in…
- Trial name
- RESPOND (NCT01135914)
- Testing
- ranibizumab, Laser
- Where
- 20 sites in Canada
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
- Trial name
- NCT04537884
- Testing
- UBX1325
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and…
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT03499223
- Testing
- Ranibizumab 0.5mg, THR-317 8mg
- Where
- 37 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Oxurion
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of DS-7080a for the Treatment of Macular Degeneration
The purpose of this study is to test DS-7080a, a monoclonal antibody, as a new treatment for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME).
- Trial name
- NCT02530918
- Testing
- DS-7080a, Ranibizumab
- Where
- 12 sites in United States
- Volunteers
- 56 people
- Sponsor
- Daiichi Sankyo
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
Primary objective: To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular…
- Trial name
- NCT03969303
- Testing
- Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Notal Vision Ltd.
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Macular Degeneration
Evaluation of the Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04499703
- Testing
- RHMS-RTM, SD-OCT
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.
- Trial name
- NCT05105607
- Testing
- D-4517.2
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Retinitis Pigmentosa (RP), Age Related Macular Degeneration
Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR).
- Conditions
- Retinitis Pigmentosa (RP), Age Related Macular Degeneration, Diabetic Retinopathy
- Trial name
- Retino (NCT06787482)
- Testing
- ACE Retino
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Ace Cells Lab Limited
Macular Edema
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
- Trial name
- NCT00782717
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Nepafenac ophthalmic suspension vehicle, Prednisolone acetate ophthalmic suspension (OMNIPRED)
- Volunteers
- 263 people
- Sponsor
- Alcon Research